The primary objective of the pilot study is to assess the feasibility of a definitive trial to determine the effect of arthroscopic soft tissue stabilization vs. non-surgical treatment on rates of recurrent anterior dislocation and functional…
ID
Source
Brief title
Condition
- Joint disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The success of the pilot study will be based upon the following a priori
thresholds:
1. 50 patients recruited within 10 months;
2. 42 of 50 participants (85%) achieving complete follow-up at two years;
3. 85% of patients allocated to surgical intervention receiving surgery within
3 months of enrollment;
4. Less than 5 crossovers* between both groups.
*Note: Crossovers are defined as either: 1) participants randomized to
non-operative management (control group) who choose to undergo surgery in the
absence of any feelings of recurrent instability or re-dislocation; or 2)
participants randomized to surgical intervention who opt out of surgery prior
to surgical intervention and choose to undergo primary non-operative management.
We will confirm feasibility with a *traffic light* approach to determine if the
definitive trial will be feasible, require modifications or will not be
feasible.
Secondary outcome
The secondary objectives of the pilot trial will be the clinical objectives of
the definitive trial:
1. Rates of recurrent shoulder dislocations up to 24 months* post-treatment;
2. Symptoms of instability without dislocation up to 24 months post treatment;
3. Clinical outcomes measured by Western Ontario Shoulder Instability (WOSI)
Index, American Shoulder and Elbow Society (ASES) score, Shoulder Activity
Scale, EQ-5D, Visual Analog Scale (VAS) Pain Score, and Patient Satisfaction
questionnaire;
4. Physical examination: range of motion, strength, stability;
5. Return to previous level of activity and work, and;
6. Safety, shoulder-related complications and serious adverse events.
Hypothesis: We believe that the pilot trial will be feasible in our ability to
recruit participants rapidly and meet our feasibility objectives.
Background summary
The shoulder is the most commonly dislocated joint in the body with a global
incidence that ranges from 15 to 25 per 100 000 people. The estimated annual
societal cost in North America due to first-time shoulder dislocations exceeds
$1.2 billion CAD.
Anterior dislocations, the most common type of shoulder dislocation, are often
complicated by subsequent instability and recurrent dislocation, with reported
rates as high as 47%. Shoulder instability commonly results in pain and
negatively impacts quality of life.
Current standard of care suggests surgical stabilization of the shoulder after
two or more dislocations, but the evidence is far from conclusive.
Observational studies suggest that early surgical stabilization has strong
biological rationale in limited risks of recurrent dislocation, improving
quality of life, and potentially decreasing the future risk of shoulder
arthritis. Also, some economic health studies suggests that surgery is less
costly and more effective, even after recurrent dislocations.
Study objective
The primary objective of the pilot study is to assess the feasibility of a
definitive trial to determine the effect of arthroscopic soft tissue
stabilization vs. non-surgical treatment on rates of recurrent anterior
dislocation and functional outcomes in patients presenting with a first-time
dislocation (FTD) over a 24-month period.
Study design
We propose a multi-centre pilot RCT of 50 participants across Canada, the
United States, South America, and Europe to compare the effect of arthroscopic
soft tissue stabilization (Bankart procedure) and non-operative treatment
(physical therapy) in patients with a post-traumatic anterior FTD. Eligible and
consenting participants will be followed-up by the site for 24 months. Outcomes
will be assessed at 6 weeks, 6 months, 12 months, and 24 months post-treatment.
Intervention
Participants will undergo arthroscopic soft tissue stabilization (Bankart
procedure) or non-surgical treatment as described below.
Arthroscopic Stabilization (Intervention)
Patients randomized to surgical intervention will be required to undergo
surgery within 3 months of enrollment. Advanced imaging will be obtained prior
to surgery, including MRI, MR arthrogram or preoperative CT scan for assessment
of pathology. For arthroscopic Bankart repair, the participant will be placed
in the lateral decubitus or beach chair position. Standard diagnostic
arthroscopy will be performed. The capsulolabral complex will be freed from the
anterior aspect of the scapular neck. The anterior aspect of the scapular neck
will be decorticated using a motorized burr. A capsuloligamentous repair will
be performed with the capsule shifted from inferior to superior and repaired on
the glenoid face. The number of anchors used for the repair will be left to the
discretion of the surgeon (a minimum of 3 anchors recommended). Remplissage
procedure will be performed at the discretion of the operating surgeon.
All participants will follow a standardized rehabilitation protocol following
surgical intervention: Phase I: Immediate postop phase (0-6 weeks) in sling,
Passive range of movement, Phase II: Active motion phase (5-8 weeks after
surgery), Phase III: Strengthening phase (8-12 weeks after surgery), Phase IV:
Advanced strengthening phase (12 weeks and beyond).
Non-surgical treatment (Control Group)
Type of sling and immobilization will be left to the discretion of the
operating surgeon. Patients randomized to non-surgical treatment will begin
early physical therapy (PT) immediately as per protocol (2 weeks after initial
immobilization). All participants will follow a standardized 3 phase
rehabilitation protocol following 2 weeks of immobilization.
Study burden and risks
Following the initial urgent management and relocation of a dislocated
shoulder, the prevention of recurrent instability is the critical management
consideration for health care providers and surgeons. Two initial management
options exist in patients with a FTD: non-operative care or surgical
stabilization.
Recent research and available evidence over the past 10 years have called into
question the role of a delayed approach to managing FTDs for a number of
reasons. Surgical management has been suggested as a more reliable option to
prevent further dislocations and improve patient outcomes when compared with
non-operative management. Arthroscopic soft tissue repair (Bankart repair) has
become increasingly popular given advancements in surgical technique allowing
for a minimally invasive and reliable improvement in shoulder stability with a
low risk of complication. The high recurrence rate in younger patients may
justify offering surgical treatment after the first dislocation episode. A
recent systematic review by Hurley et al.16 found arthroscopic Bankart repair
resulted in a 7-fold lower recurrence rate and a higher rate of return to sport
and activity than non-operative management21. While other surgical
stabilization options exist, including non-anatomic bony transfer (Latarjet
procedure), the Bankart repair is widespread as it is minimally invasive and
restores native anatomy. Recent data also suggests that patients who are
surgically treated following a FTD have improved outcomes when compared to
those who have recurrent instability events before undergoing surgery.
Delayed management of shoulder instability results in further injury to the
shoulder joint. MRI evaluation of individuals who were assessed greater than 6
months from the time of initial dislocation had increased prevalence of not
only recurrent shoulder instability events but a greater incidence and severity
of intra-articular injury, including SLAP tears, labral tears, and glenoid
cartilage damage.
Charlton Ave E T3302-50
Hamilton L8N 4A6
CA
Charlton Ave E T3302-50
Hamilton L8N 4A6
CA
Listed location countries
Age
Inclusion criteria
1. Patients ages 18-40 years;
2. Diagnosis of first-time anterior shoulder dislocation having occurred within
the past 3 months, confirmed either by radiographic evidence or documented
reduction of anterior shoulder dislocation as well as physical examination
eliciting unwanted glenohumeral translation with reproduction of symptoms;
3. Provision of informed consent.
Exclusion criteria
1. Patients that cannot undergo surgery or anesthesia;
2. Patients with concomitant injuries (rotator cuff tear, fracture);
3. Previous shoulder surgery;
4. Patients that will likely have problems with maintaining follow-up or are
incarcerated;
5. Epilepsy/seizure disorder
6. Pregnancy;
7. Diagnosis of multidirectional instability;
8. Bony glenoid defect (bony Bankart) >10% as measured on preop imaging;
9. Dislocation without trauma, in a context of hyper laxity or atraumatic
instability;
10. Cases involving litigation or workplace insurance claims (e.g. WSIB).
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
ClinicalTrials.gov | NCT05715021 |
CCMO | NL86808.100.24 |